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ABSTRACT 
Amlodipine is the best-prescribed medication for cardiovascular disease major risk factor for hypertension and atorvastatin well known for 
diabetic. First discussed low cost ultraviolet-visible technique for the determination and quantitation of drugs in pharmaceuticals and biological 
fluids. Chromatographic techniques have an application with respect to trace analysis. Different types of chromatography such as high-performance 
liquid chromatography, high performance thin layer chromatography have most frequent applications in the field of pharmaceutical as well as 
biomedical analyses. Chromatography combined with mass spectrophotometry has the ability to collect molecular ion, followed to prepare a 
spectrum to assess molecular weight as well as structure. High-performance liquid chromatography coupled with mass spectrophotometry is a 
reliable and dynamic technique for the analysis of small and large drugs molecule. The advantages and disadvantages of all techniques are 
compared with each other with respect to sensitivity, reproducibility and other important parameters. The investigation also focused for the 
quantitation on both drugs in pharmaceutical preparations and plasma samples with the help of all available analytical techniques.  
Keywords: Drugs, Amlodipine, Atorvastatin, HPLC, UPLC, TLC, HPTLC, CE, LCMS, UP-LCMS 




Amlodipine besylate (fig. 1a) is scientifically known as (RS)-3-ethyl-
5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro 
-6-methyl-3,5-pyridinedicarboxylate benzene sulfonate. It was first 
introduced and prescribed for coronary artery disease. It was also 
helpful for angina and peripheral artery disease [1]. Now days 
mostly targeted for the patient having hypertension. The European 
Society of Cardiology was conducted survey until the year 2000 and 
their report based on statistical analysis showed nine hundred 
seventy-two million people were in this category. The number will 
increase with time and expected by the year 2025, approximately 
1.56 billion [2]. This drug is under the umbrella of calcium channel 
blocker. The mechanism of such blockers to control the transportation of 
calcium to coronary (mainly smooth muscle) and arteries, that reflects 
on muscles became relaxes, reduces peripheral resistance and ultimately 
lowering the blood pressure [3]. Atorvastatin (fig. 1b) is chemically 




     
(a)       (b) 
Fig. 1: Structure of amlodipine (a) and atorvastatin (b) 
 
The synthetic drug, atorvastatin is generally under the class known 
statins. These reductase inhibitors are familiar as 3–hydroxyl–3–
methylglutaryl–coenzyme A (HMG–CoA). All drugs are prescribed 
for cardiovascular disease and reduction of heart attack, as well as 
for clinical demand [4–10]. Active pharmaceutical ingredients (APIs) 
such as amlodipine are commonly manufactured as their acid 
addition salts to promote solubility and improve both stability and 
bioavailability. The objective of this review article was to research 
more about ultraviolet–visible and chromatographic technique's 
applications, specifically for the quantification of amlodipine and 
atorvastatin in bulk, pharmaceutical formulations, and biological 
fluids. Compared the result between all the developed method for 
amlodipine and atorvastatin about the limit of detection and 
quantitation value. Discussed briefly the importance of all analytical 




Spectroscopic methods are mostly used for the determination of drugs in 
bulk as well as with pharmaceutical formulations. Ultraviolet (UV) and 
visible spectrophotometry are important and common techniques for 
the quantitative analysis of drugs. Because these are low-cost 
techniques, simple and no requirement of pretreatment as well as any 
elaborate preparatory step prior to assay. The visible spectrophotometer 
is depending on the redox and complex formation reaction. However, 
some deficiencies are also with the techniques with respect to the 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 11, Issue 3, 2019 
haque et al. 
Int J App Pharm, Vol 11, Issue 3, 2019, 5-15 
 
6 
presence of two or more drugs have similar UV characteristic. The 
detailed literature survey studies elaborate on the advantages and 
disadvantages among all developed method for both drugs using UV–
visible spectrophotometer [11–38] are presented in table 1. 
 
Table 1: Determination of amlodipine and atorvastatin using uv–visible spectrophotometer 
Drug Reagent/Solvent λmax Application  (nm) Reference 
Amlodipine  
Besylate 
Chloramin-T 390 Bulk powder [11] 
Methanol 239, 238 Bulk drug and tablets [12] 
Ethanol 343 Rat plasma [13] 
Water 238 Tablets [14] 
Methanol, HCl 240 Tablets [15] 
7,7,8,8-tetracyanoquinodimethane  
(TCNQ), tetracyanoethylene (TCNE) 
745, 396 Pure and dosage form [16] 
Phosphoric acid and water 366 Pure and dosage form [17] 
Methanol 360 Pharmaceutical dosage forms [18] 
HCl 239 Bulk and tablets [19] 
Methanol 360 Bulk and tablet dosage form [20] 
Methanol 200–350 Tablets [21] 
Methanol 359 Bulk mixture and tablets [22] 
Methanol 360 Tablets [23] 
Methanol: Water (50:50, v/v) 241 Tablet [24] 
Methanol and water 239, 245 Tablet dosage form [25] 
Urea solution 243 Bulk and pharmaceutical dosage form [26] 
Water 366, 239 Pure sample and tablets [27] 
Methanol 239 Tablet dosage form [28] 
Atorvastatin 
Calcium 
Methanol 247 Pure and tablets [29] 
p-dimethylaminobenzaldehyde 540 Bulk and dosage form [30] 
Pararosaniline HCl 547 Tablet [31] 
Iodine 291, 360 Pure and pharmaceutical formulations [32] 
ACN: Water =70:30,v/v 268, 245 Tablet dosage form [33] 
Methanol 247 Bulk and pharmaceutical dosage form [34] 
Methanol 244 API and tablet [35] 
Methanol 246 Tablet dosage form [36] 
Methanol: Water (50:50, v/v) 250 Tablet [24] 
Urea, Ferric chloride and potassium ferricyanide 240, 787 Tablets and biological fluids [37] 
Methanol 246 API and pharmaceutical formulations [38] 
 
High performance liquid chromatography  
High-performance liquid chromatography (HPLC) technique is 
more accurate and based on the properties of the analyte with the 
existing mobile phase and stationary phase. Depending on the 
stationary and mobile phase, different types of chromatography 
techniques are developed. Recently high-performance liquid 
chromatography has achieved lots of attention in the field of 
pharmaceutical analysis in dosage forms and biological fluids 
because of its simplicity, sensitivity and high specificity. The 
conventional rule for the analysis of polar compounds by utilizing 
a non-polar stationary phase with the polar mobile phase and vice 
versa for the non-polar compounds. Stationary phase binding the 
analyte is directly proportional with the surface area of the non-
polar segment of the analyte associate the ligand as well as with 
aqueous eluent. One of the main parameters found as evidence 
about the quality and efficacy of drug products and formulations is 
stability testing. The products nature is changing with humidity, 
temperature, light, retesting time, storage conditions, shelf life, so 
it is necessary to control the environmental factors. To develop 
method different types of the column (ODS C 18, BDS C 8, ODS C 8, 
BDS C 18 and Discovery HS C 18
The ultra-performance liquid chromatography (UPLC) is a new and 
modern technique for liquid chromatography. Worldwide HPLC was 
a predominant technique for the last 30 to 40 y for the drug analysis. 
Speed, sensitivity, and resolution are the main keywords for the 
drugs analysis with UPLC compare to HPLC. The particle size can 
play a significant role in this type of chromatography that governed 
by the well-known Van Deemter equation. For UPLC, the preferred 
size diameter is less than 2μm to get more sensitivity, short analysis 
time and improved resolution. The quality of the product analyzed 
by UPLC will give better with less time. However, the main 
disadvantage is related to the column life. The analysis requiring 
high pressure (100 M Pa) that damage the column efficiency. The 
novel and selective methods were developed for the determination 
of both drugs with a marketed formulation as single or combined 
dosage form [84–98] (table 3). 
Thin layer chromatography 
) with a combination of different 
mobile phases containing buffers, organic modifier (acetonitrile, 
methanol) can be used. Amlodipine and atorvastatin were 
quantified using HPLC with ultraviolet in bulk and pharmaceutical 
dosage form [39–83] (table 2). 
Ultra pressure liquid chromatography  
Thin-layer chromatography (TLC) is a simple separation technique 
typically for the mixture of nonvolatile compounds. The adsorbent 
material, specifically cellulose, silica gel, aluminum oxide is 
covered on plastic or glass sheet, known as the stationary phase. 
Aleppo bentonite with modified phenyl support can also be 
applied as the stationary phase, has the ability to separate 
amlodipine and atorvastatin with a mobile phase consisting of 
sodium phosphate buffer and acetonitrile (50:45, v/v) in 
pharmaceutical dosage form [99]. Methanol, toluene triethylamine 
combination and silica gel adsorbent distinct atorvastatin in 
pharmaceutical formulation with high resolution [100]. However, 
triethylamine can be replaced with chloroform and acetic acid in 
tablet dosage form on the aluminum plate [101]. However, 
propanol and water system (70:30, v/v) has the capability to 
separate amlodipine with a detection limit of 0.4 µg [102]. 
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Table 2: Important parameters for the determination of drugs using HPLC 








TEA buffer (pH 3) and ACN = 25:75, 
v/v 
Stainless steel C18 1.0 
(4.6×150 mm, 5 µm) 




0.1% OPA: Acetonitrile = 70:30, v/v Phenomenex C18 0.7  




Phosphate Buffer (pH 4.5): 
Acetonitrile = 55: 45,v/v 
Phenomenex C18 1.0  
(25×0.46 cm, 5μm) 
224 Tablet [41] 
Potassium dihydrogen phosphate 
buffer (pH 5.3): Acetonitrile = 55:45, 
v/v 
Shodex RP C18 1.0  (250 ×4.6 
mm, 5 μm) 
237 Pure and dosage 
form 
[42] 
Ammonium acetate (0.5 M, pH 6.8 at 
0.5): Acetonitrile = 40:60, v/v 
Eclipse XDB C18 0.5 (4.6×250 
mm, 5 μm) 




orthophosphate (0.05M, pH 3.5): 
Acetonitrile = 45:55, v/v 





Phosphoric acid (0.025 M) and 
Acetonitrile 
Zorbax SB-C8 1.0  (4.6×250 




Phosphate buffer: Methanol (73:27, 
v/v) 
Zorbax Eclipse Plus 
(150x4.6 mm, 5μm) 
1.1 270 Tablets [46] 
Mobile phase A–Phosphate buffer, pH 
2.8: Methanol=60:40, v/v 
Mobile phase B–Phosphate buffer, pH 
2.8: Methanol: Acetonitrile 
=20:40:40, v/v/v 
Inertsil ODS-3 C18 1.0  
(150×4.6 mm, 3μm) 
340 Tablet formulation [47] 
Phosphate buffer (pH=3): 
Acetonitrile: Methanol = 
25:45:30,v/v/v  
Zorbax ODS (4.6x250 
mm, 5 µm) 
1.0 254 Tablets [48] 
Acetonitrile=Methanol (70:30, v/v) Hypersil C18 1.0  (250×4.60 
mm, 5μm) 




Potassium dihydrogen phosphate 
(pH 5.5, 0.03M)-Acetonitrile (65:35, 
v/v) 
Phenomenex C18 1.2  
(250x4.6 mm, 2.6μm) 
240 Tablets [50] 
Potassium dihydrogen 
orthophosphate buffer (50 mmol, pH 
3.7): Acetonitrile = (56:44, v/v) 
Kromasil KR 5 C18 1.0 





orthophosphate buffer (pH 
3.2):Acetonitrile=(60:40, v/v) 
Hypersil gold C18 1.0 




Acetonitrile, water and potassium 
dihydrogen phosphate buffer pH 2.7 
(45:35:20,v/v/v) 
Phenomenex Luna 
(250×4.60 mm, 5 µm) 
1.0 230 Tablet dosage form [53] 
Acetonitrile-Phosphate buffer (0.05 
M, pH 2.8):Acetonitrile (60:40, v/v) 
Phenomenex Kinetex 
(150×4.6 mm) 
0.8 227 Tablet and human 
plasma 
[54] 
Phosphate buffer pH 4.0: Acetonitrile 
(40:60, v/v) 
ODS C18 1.0  (250 mm×4.6 
mm, 5μm) 
247 Bulk and tablet 
dosage form 
[55] 
Potassium dihydrogen phosphate 
buffer (pH 4.5): Methanol 
(25:75,v/v) 
Prontosil C18 1.4 (250 × 4.6 
mm, 5 µm) 
240 Tablet formulation [56] 
Acetonitrile and water (60:40, v/v) HIQ SII C18 1.0  -10 (250x4.5 
mm) 




Ammonium acetate buffer (10 mmol, 
pH 4): Acetonitrile (40:60, v/v) 
Symmetry C18 1.0, 2.0  (75×4.6 
mm, 3.5 µm)  
220 Tablet dosage form [58] 
Potassium dihydrogen 
orthophosphate buffer (pH 
3.2):Acetonitrile=(52:48, v/v) 
Kromasil C18 1.0 (150×4.6 
mm, 5 µm) 
210 Tablet dosage form [59] 
Acetonitrile: dichloromethane: acetic 
acid (68.6:30.6:0.8, v/v/v) 
Acclaim 120 C18 1.0  




0.01N Sodium dihydrogen ortho 
phosphate buffer (pH 4): Methanol = 
50:50, v/v 
Kromasil C18 1.0  (150x4.6 
mm, 5 µm) 
240 Tablet dosage form [61] 
Water (pH 4.5, adjusted with 
phosphoric acid): Acetonitrile = 
15:85, v/v 
Zorbax SB C18 1.0  (150×4.6 
mm, 3.5 µm) 
261 Tablet formulation [62] 
Phosphate buffer (pH=3): 
Acetonitrile: Methanol = 
25:45:30,v/v/v  
Zorbax ODS (4.6x250 
mm, 5 µm) 
1.0 254 Tablets [48] 
Potassium dihydrogen phosphate (10 
Mm, pH 3): Acetonitrile = 59:41,v/v 
Kromasil 100 C18 1.0  
(250x4.6 mm, 5 µm) 
245 Tablets [63] 
Ammonium dihydrogen phosphate 
buffer (pH 5): Methanol = 60:40, v/v 





Phosphate buffer (pH 3.3): Agilent XDB C18 1.0  (150×4.6 280 Bulk and [65] 
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Buffer (pH 5):Acetonitrile=(60:40, 
v/v) 






(0.1%):Acetonitrile =66:34, v/v 
Kromasil 100 C18 1.0 (25 
cmx4.6 mm, 5μm) 
246 Bulk and tablets [67] 
Solvent A–10 mmol Phosphoric acid 
buffer (pH=2.6)  
Solvent B–Acetonitrile 
Solvent C–Methanol  
BDS Hypersil C18 1.0  
(250×4.6 mm, 5 𝜇𝜇m) 
220 Human plasma [68] 
Potassium dihydrogen phosphate 
(pH 4.5): Acetonitrile = 30:70,v/v 
Inertsil C18 1.0  ODS (4.6x250 
mm, 5 mm) 
254 Tablet dosage form [69] 
Potassium dihydrogen phosphate 
(pH 5.5, 0.03M)-Acetonitrile = 
(65:35, v/v) 
Phenomenex C18 1.2  
(250x4.6 mm, 2.6μm) 
240 Tablets [50] 
Acetic acid solution (0.1%, pH 3.8): 
Acetonitrile = 45:55 v/v 
Cartridge–LiChroCARTR 
(250×4 mm) Column–
LiChrospher 100 RP-18, 
5 μm  
0.8 246 Tablets [70] 
Potassium dihydrogen 
orthophosphate buffer (0.025 M, pH 
5): Acetonitrile = 55:45 v/v 
Eclipse XDB (4.6x150 
mm, 5 µm) 
1.5 246 Pharmaceutical 
formulations 
[71] 
Acetonitrile: Phosphate buffer (10 
mmol, pH 3): Acetonitrile = 45:55 v/v 
Altima C18 1.0  (25 cm× 4.6 
mm, 5μm) 
240 Bulk and dosage 
form 
[72] 
KH2PO4 Capcell pak C (50 mmol, pH 4.1): 
Acetonitrile = 28:72 v/v 
8 1.0  (4.6x250 




Ammonium acetate buffer (pH 3): 
Acetonitrile = 50:50, v/v 
Phenomenex C18 1.2  




Potassium dihydrogen phosphate 
(0.02 M) buffer: Methanol: 
Acetonitrile=10:50:40, v/v/v 
Zorbax SB C18 1.1  (250×4.6 
mm, 5 µm) 
236 API and 
formulations 
[75] 
Potassium dihydrogen phosphate (10 
mmol, pH 3.0): Acetonitrile = 60:40, 
v/v 





Water (pH 3.2 with phosphoric acid): 
Methanol = 10:90, v/v 
HiQ Sil C8 1.0  (4.6×250 mm) 260 Tablet dosage form [77] 
Sodium phosphate buffer (0.05 M, pH 
4.1): methanol = 30:70, v/v 
LiChrosphera C18 1.0  
(250x4.6 mm, 5 mm) 
247 Bulk and tablet 
formulation 
[78] 
Acetate buffer (pH 3.7): methanol = 
18:82, v/v 
Luna C18 1.5 (250×4.6 mm, 
5μm) 
248 Tablet dosage form [79] 
Ammonium acetate buffer (0.01 M, 
pH 3): Acetonitrile = 50∶50, v/v 
Inertsil ODS (250 
mm×4.6 mm, 5 μm) 
1.0 254 Pharmaceutical 
formulations 
[80] 
Potassium dihydrogen phosphate 
buffer (0.02 M, pH 4): methanol = 
20:80, v/v 
Phenomenex C18 1.0  
(250×4.6 mm, 5 μm) 
240 Capsule dosage 
form 
[81] 
Water (pH 2 with phosphoric acid): 
Acetonitrile = 48:52, v/v 
LiChrospher ODS, 
LiChrosorb ODS, 







Ammonium acetate buffer (pH 4): 
Acetonitrile: THF = 70:25:5, v/v/v 
Luna C18 1.0 (250×4.6 mm, 
5μm) 




High-performance thin layer chromatography 
High-performance thin layer chromatography (HPTLC) is an 
accelerated separation technique and flexible enough to determine 
the drug sample. The advantages associated with HPTLC are a short 
analysis time for the complex sample without pretreatment, 
independent construction of chromatogram with multiple samples, 
easy to transfer samples that will increase the confidence and 
reliability of the technique. It can be employed for qualitative and 
quantitative purposes. Several combinations of mobile phases with 
different size of plates have been successfully studied by HPTLC in 
pharmaceutical preparations [103–115] (table 4).  
Capillary electrophoresis 
Capillary electrophoresis (CE) is based on charge and size under electric 
field separate molecules. The capillary tube is made of glass loaded with 
an electrolyte solution. Electrophoretic mobility is an important 
parameter for the separation, chemical constituents as well as solvent 
viscosity. However, the limitation with gel electrophoresis with regards 
to applied voltage due to ohmic heating damage the gels and restrict the 
separation. Need to require large voltage often 10–20 thousand for 
experiments with CE. Different types of capillary electrophoresis are 
capillary zone electrophoresis (CZE), capillary gel electrophoresis (CGE), 
micellar electrokinetic capillary chromatography (MEKC), capillary 
electro chromatography (CEC), capillary isoelectric focusing (CIEF) and 
capillary isotachophoresis (CITP). 
Phosphate buffer (pH 6.5) and methanol mixture combined (80:20, v/v) 
used as background electrolyte with capillary fused silica column under 
15 KV voltage at room temperature for the determination amlodipine 
and atorvastatin [116]. In tablet formulation no interference from 
present common excipients [117]. Phosphate buffer can separate both 
drugs in 5 min with high precision but in the presence of acidic products 
need to involve borate buffer [118–119]. It is likewise possible to 
quantify within 3 min in combined dosage form with high efficiency and 
resolution [120]. CZE method validated for solid dosage form in the 
presence of electrolyte as a methanol borate buffer [121]. MEKC 
succeeded by controlling surfactant, sodium dodecyl sulfate (SDS) 
concentration and acquired within 2 min [122] compared to CZE [117] 
13 min migration time having comparable resolution. 
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Table 3: Determination of amlodipine and atorvastatin in bulk and pharmaceutical formulations using UPLC 











Mobile phase A–Trifluoro acetic 
acid in water (0.1%), Mobile 
phase B–Acetonitrile 
BEH C18 0.6 (2.1×30 
mm, 1.7μm) 




Potassium dihydrogen ortho 
phosphate Buffer (pH 2.4): 
Acetonitrile = 40: 60,v/v 
C18 0.5  (4.6x50 
mm,3.5 μm) 
240 10.0 Tablet dosage 
form 
[85] 
Phosphate buffer (pH 3): 
Acetonitrile = 55:45, v/v 
Kinetex C18 1.0  
(4.6x150 
mm,2.6μm) 
230 6.0 Dosage form [86] 
Glacial acetic acid (1%) buffer: 
Acetonitrile = 58:42, v/v 
BEH C18 0.25  2.1×100 
mm,1.7 μm) 




phosphate buffer (0.02 M): 
Acetonitrile = 45:55, v/v 
BEH C18 0.3  
(100×2.1 
mm,1.7μm) 
242 5.0 Tablet dosage 
form 
[88] 
Triethyl amine buffer (0.1%, pH 
3) and buffer; Gradient elution 
Kromasil C18 0.8  
(50×2.1 mm,3.5 
μm) 
240 2.2 Pharmaceutical 
dosage form 
[89] 
Mobile phase A-Sodium 
perchlorate buffer (0.053 M, pH 
3.2): Acetonitrile = 90:10, v/v  
Mobile phase B-Sodium 
perchlorate buffer (0.053 M, pH 
3.2): Acetonitrile = 20:80, v/v 
Gradient programme  
BEH RP18 0.6 
(100x2.1 
mm,1.7μm) 
237 4.5 Tablets [90] 
Mobile phase A: Ammonium 
acetate buffer (5 mmol, pH 4) 
Mobile phase B: Buffer: 
Acetonitrile (10: 90, v/v) 
Gradient programme 
BEH C18 0.613  (50×2.1 
mm, 1.7 μm) 






phosphate buffer (10 mmol, pH 
3): Acetonitrile = 50:50, v/v 
Thermo C18 0.3  (50x 
2.1 mm,1.9 μm) 
255 2.5 Tablet [92] 
O-phosphoric acid (1%): 
Acetonitrile = 55:45, v/v 
Phenomenex C18 1.0  
(100×4.6 mm, 
2.6 μm) 
254 10.0 Tablets [93] 
Ammonium acetate buffer (0.01 
M, pH 6.7) and Acetonitrile; 
Gradient programme 
Kromasil C18 0.2  
(2.1×50 mm, 2.5 
µm) 
245 5.0 Bulk drug and 
tablet 
[94] 
Triethyl amine buffer (0.1%, pH 





 (50×2.1 mm, 
3.5 μm) 
240 2.2 Pharmaceutical 
dosage form 
[89] 
Phosphoric acid (0.02 M) buffer 
and acetonitrile; Gradient 
programme 
Zorbax C18 0.5  
(50×3.0 mm,1.8 
μm) 
------ 12.0 Bulk drug [95] 
Orthophosphoric acid (0.1%) 
and acetonitrile = 55:45, v/v 
BEH C18 0.35  (2.1×50 
mm,1.7 μm) 
230 4.0 Capsule dosage 
form 
[96] 
Perchloric acid (0.1%, adjusted 
to pH 2.5) and Acetonitrile; 
Gradient programme  
BEH C18 0.6  
(100×2.1 mm,1.7 
μm) 
215 3.0 Tablet dosage 
form 
[97] 
Buffer, ortho phosphoric acid 
(0.06%) with ion pair reagent 
sodium lauryl sulfate (0.045M) 
and Acetonitrile = 50:50, v/v 
Zorbax C18 1.0  
(4.6x50 mm,1.8 
μm) 




High and ultra-pressure liquid chromatography combined with 
mass spectrophotometry 
High pressure and ultra-performance liquid chromatography with the 
mass spectrometry (LC-MS, UPLC-MS) are analytical techniques that 
combine liquid chromatography with mass spectrophotometer. The 
aim to develop a fast and reliable analytical method for the 
determination of atorvastatin and amlodipine together with the 
presence of metabolites using the above techniques. The MS combined 
with LC has high selectivity and sensitivity. The techniques are 
commonly applied for bioavailability and pharmacokinetics 
investigation. Mostly quantification of parent drug, active and inactive 
metabolites are of interest for various studies with biological fluids. It 
is also required to verify the interaction between drug to drug and side 
effects as well as the toxicity of different metabolites after metabolism 
in the human body. The LCMS [123–136] (table 5) and UPLC-MS [137–
142] (table 6) were used for the determination of amlodipine, 
atorvastatin and their metabolites in pharmaceutical dosage forms 
and biological fluids. 
DISCUSSION 
The UV-visible spectrophotometer does not require any pH 
adjustment and very close to the pharmacopeia method for both 
drugs. Recently HPTLC can be applied as an alternative option for 
traditional TLC method. It is easy to handle with software, which is 
not possible with TLC. HPTLC enhanced the capability to determine 
impurity with the help of the hydrophilic phase combined silica gel, 
an important parameter in all pharmacopoeias. One single run is 
enough to achieve two parameters such quantity and its impurity by 
HPLC, main pharmacopeias method to quantify the assay 
haque et al. 
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percentage. The setting of parameters for the reaction is not easy as 
well as for characterization with CE that is why maybe not 
recommended in official method. UPLC is a high-cost instrument 
compare with other chromatographic methods, ability to study 
pharmacokinetics such as adsorption, metabolism. The limit of 
detection (LOD) and limit of quantitation (LOQ) value is very less 
with chromatographic method combined with mass spectro-
photometry (table 7). Amlodipine and atorvastatin concentration in 
pharmaceutical formulations and biological fluids are based on 
different parameters and the calibration curve of the analyte (table 
8). During method development and validation, accurately 
quantified the analyte as well provide brief information related to 
impurity profiling, a
 
 key equipment for the formulation process of 
the drug. 
Table 4: Determination of drugs using HPTLC in pharmaceutical preparations 





Acetonitrile: Water: Toluene 
(60:30:10, v/v/v) 




270  Tablet formulation [103] 
Ethyl acetate: Methanol: 
Ammonia (7.5:2:0.5, v/v/v) 
Aluminium plate (20×10 cm, 0.2 
mm) coated with Silica Gel 60 F
0.50  
254 
365 Dosage form [104] 
Chloroform: Butan-1-ol: 
Ammonia (6: 4: 0.1, v/v/v) 
Aluminium plate (10×10 cm, 
washed with methanol) coated 
with Silica Gel 60 F
0.27 
254 
254 Tablet dosage form [105] 
Chloroform: Toluene: Methanol: 
Acetic acid (6: 2.5: 1.5: 0.5, 
v/v/v/v) 
Aluminium plates (10×10 cm) 
precoated with silica gel 60 F
0.3 
254 
244 Synthetic mixture [106] 
Aluminium plates Methanol: Toluene: Ethyl acetate: 
10% Ammonia solution 
(2:3.5:5:1, v/v/v) 
(10x10 cm, 0.2 







Toluene: Ethyl acetate: Methanol: 
Triethylamine (4:1:1:0.4, v/v/v) 
Aluminium plates (10x10 cm, 0.2 




254 Bulk and tablets [108] 
Methanol: n-butanol: 25% 
Ammonia solution (4:4:2, v/v/v) 
Plates (10 mm, bottom and 10 mm, 
side edges, band length 6 mm) 
precoated with silica gel 





Chloroform: Methanol: Toluene: 
Ammonia (5:2:1:0.2, v/v/v/v) 
Aluminium plates (20×10 cm) 
precoated with silica gel 60 F
0.17 
254 
289 Tablet dosage form [110] 
Ethyl acetate: Methanol: 
Ammonia (7.5:2:0.5, v/v/v)  
Aluminium plate (20×10 cm, 0.2 
mm) coated with Silica Gel 60 F
0.26 
254 
365 Dosage form [104] 
Toluene: Ethyl acetate: Methanol: 
Glacial Acetic Acid (7:2:1:0.1, 
v/v/v/v) 
Precoated silica gel 60 F254 TLC 
plates (20×20 cm2
0.38 




Toluene: Methanol (8:2, v/v) Plate precoated with silica gel 60 
F254
0.15 
 (20×10 cm, 0.2 mm) 
260 Dosage form [112] 
Toluene: Methanol: Ethyl acetate: 
Acetic acid (5: 1:1:0.3, v/v/v/v) 
Plate coated with silica gel 60 F254 0.63 




Acetonitrile: Methanol: Ethyl 
acetate: Glacial Acetic Acid 
(2:4:4:0.06, v/v/v/v) 
Precoated silica gel 60 F254 0.77  (10×10 




Toluene: Methanol: Ethyl 
Acetate: Glacial Acetic Acid (7: 
1.5: 1: 0.5, v/v/v/v) 
Aluminum backed silica gel 60 F254 0.28  
plates (10×10 cm) 
276 Capsules [115] 
 
Table 5: Determination of drugs in biological fluids using LCMS 





Acetonitrile: Water (10 mmol ammoniumacetate, 0.5% 
ammonia Solution) = 95:5, v/v 
Chiralcel OZ-RH 
(150×4.6 mm, 5 μm) 
0.5 Rat plasma [123] 
Ammonium acetate in 0.1% formic acid: Methanol: 
Acetonitrile=40:30:30, v/v/v 





Acetonitrile: Ammonium formate (2 mmol, pH 4) = 90:10, 
v/v 





Acetonitrile: Water (10 mmol CH3COONH4 Zorbax XDB C, pH 3.0) = 70:30, 
v/v 
18 0.15  




Acetonitrile: Formic acid (10 mmol) = 80:20, v/v Atlantis dC18 0.3  (2.1x100 




Acetonitrile: Ammonium formate solution (5 mmol) = 80:20, 
v/v 
Luna C18 0.8 100A 




Acetonitrile: Water (0.1% formic acid) = 50:50, v/v Aquasil C18 0.2  (50×2.1 
mm, 5 μm) 
Rat plasma [129] 
Methanol and ammonium acetate (10 mmol); Gradient 
programme 
Diamond C18 0.5–0.8  (150×4.6 






Mobile phase A–Acetonitrile Mobile phase B–0.1% CH3
Gradient programme  
COOH  Zorbax C18 0.4  (4.6×100 
mm, 3.5 μm) 
Rat plasma [131] 
Acetonitrile: Water (10 mmol CH3COONH4 Zorbax C, pH 3.0) = 70:30, 
v/v  
18 0.15  (2.1×30 




Water and methanol (modified with 2 mmol ammonium 
formate and 0.2% formic acid); Gradient programme 
Zorbax C18 0.4  (50×2.1 




 Formic acid (0.005%): Acetonitrile: Methanol = 35:25:40, Ascentiss C18 0.6  (75×4.6 Human [123] 
haque et al. 
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v/v/v mm, 2.7 μm) plasma 
Formic acid (0.2%): Acetonitrile = 30:70, v/v Agilent C18 0.6  (100×4.6 




Acetic acid buffer (0.2%): Methanol: Acetonitrile = 20:16:64, 
v/v/v 
Zorbax Phenyl (75x4.6 




Acetonitrile: Methanol: 0.1% Formic acid (0.1%) = 50: 30: 
20, v/v/v 






Table 6: Determination of drugs in dosage form and biological sample using UPLC–MS 







Mobile phase A–0.1% formic acid in 
water 
Mobile phase B–0.1% formic acid in 
acetonitrile: Methanol = 90:10, v/v 
BEH C18 0.3  (2.1×100 
mm,1.7 μm) 
5.5 Human plasma [137] 
Solvent A–0.1% formic acid in water 
Solvent B–0.1% formic acid in 
acetonitrile: water= 95:5, v/v  
Hypersil (50×2 
mm, 1.9 μm) 
0.25 5.0  Dosage form [138] 
0.1% formic acid in ammonium acetate 
buffer (0.02 M, pH 3.5): Methanol = 
25:75, v/v 
BEH C18 0.6  (50×2.1 
mm, 5 µm)  
10.0 Human plasma [139] 
Atorvastatin 
Calcium 
0.2% (v/v) formic acid in water and 
acetonitrile, gradient programme  
Leapsil C18 0.3  100×2.1 
mm, 2.7 μm) 
5.0 Human plasma [140] 
0.05% (v/v) formic acid in water: 
Acetonitrile = 25: 75, v/v 
Acquity T3 (3×100 
mm, 1.8 μm) 
0.3 4.0 Human plasma [141] 
Solvent A–0.1% formic acid in water 
Solvent B–0.1% formic acid in 
acetonitrile: water = 95:5, v/v  
Hypersil (50×2.0 
mm, 1.9 μm) 
0.25 5.0 Bulk and 
dosage form 
[138] 
Acetonitrile and Ammonium acetate 
buffer (0.05 mmol, pH 4); Gradient 
programme 
BEH C18 0.25  (100×2.1 
mm, 1.7 µm) 
5.25 Serum sample [142] 
 
Table 7: Comparison of LOD and LOQ values for amlodipine and atorvastatin with various analytical techniques 
Drugs Analytical technique Sample/Application LOD (µg/ml) LOQ (µg/ml) Reference 
Amlodipine Besylate UV–Visible  Pure and dosage form 0.291 0.963 [42] 
HPLC Pure and dosage form 0.074 0.223 [42] 
UPLC Tablet dosage form 0.02 0.062 [88] 
CE Tablets 0.13 0.44 [121] 
LCMS Human plasma 0.302 ng/ml 0.997 ng/ml [129] 
UPLCMS Dosage form 0.23 ng/ml 0.69 ng/ml [139] 
Atorvastatin Calcium UV–Visible  Pharmaceutical formulation 0.31 0.93 [31] 
HPLC Tablet dosage form 0.189 0.603 [58] 
UPLC Tablet dosage form 0.026 0.078 [88] 
CE Pharmaceutical formulations 0.27 0.89 [122] 
LCMS Human plasma 0.05 ng/ml 0.165 ng/ml [134] 
UPLCMS Dosage form 0.56 ng/ml 1.7 ng/ml [139] 
 




UV–Visible  Defective equipment designs due to stray light, linearity range 
decreases; Quality of detector affected signal measurement and 
sensitivity reduced 
Simple operation procedure, fast, cost effective, accurate in 
readings and used widely 
TLC Low reproducibility, inadequate separation length, unavailable 
automation, without scanning, less efficiency, only qualitative and 
open system 
Low cost, easy separation, require small size, visible with UV 
light, non-volatile analyte 
HPLC Difficult with coelution and adsorbed analyte, necessary mobile 
phase filtration, degassing and pH 8 (basic) impossible for 
separation, need high skilled analyst 
High resolution, repeatability, reliable data, develop method 
can modified with regards to quantification level 
HPTLC Glass plate with heavy weight, fragile, excessive cost;  
Aluminum plate loses shape above 120 C̊, prewashing desired for 
plate, concentration dependent spectral shape 
Applicable for matrix sample, not require filtration of mobile 
phase, can work with pH 8, no contamination, visual 
detection, high efficiency, no need high skilled analyst 
UPLC Involved high pressure, moderate column life, high maintenance 
cost 
Highly sensitive, less solvent consumption, small flow rate, 
decrease particle size 
CE Low repeatability, high cost, problem during characterization of 
peak, effect of matrix and parameters optimization for analyte 
Able to determine ion, charge, highly polar compound; 
different mode of separation, less volume and effluent  
HPLCMS Pretreatment of analyte before each analysis, high cost reagent, 
complex sample preparation 
Rapid analysis, short run time, large no analyte batches, easy 
to quantify parent drug and its metabolite 
UPLCMS Multi reaction monitoring, equipment cost high and necessary 
derivatization  
Robust, sensitive, capable of bioequivalence study, easy for 
biological fluids, low LOD and LOQ (table 7) 
haque et al. 




The main objective of this review is to provide sufficient information 
for the researcher, academic, scientist about the analysis of 
important calcium channel and statins receptor. After going through 
with the proposed review, people can understand the common 
method for the analysis of drugs. These medications are very 
significant due to its growing demands in our daily life that is why it 
was one of the fastest growing products in the pharmaceutical 
industry. The ultraviolet and visible spectrophotometer are low-cost 
instrument as well as easy to handle and available everywhere. It is 
more suitable for pure pharmaceutical formulations. The biological 
fluids and trace analysis will go for highly sensitive instrument 
combined with the mass spectrophotometer. Therefore, the present 
review will give an idea for determination and quantification of both 
drugs using UV–visible, HPLC, HPTLC, UPLC, LCMS and UPLC-MS in 
bulk, pharmaceutical formulations, and biological fluids.  
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